Furthermore, Rituximab may promote immunosuppression through a variety of mechanisms, including delayed-onset cytopenia, notably neutropenia and hypogammaglobulinemia. Clinical research have yielded contradictory outcomes in terms of rituximab's connection with infections. Some studies have reported increased rates of infection while others have not found evidence of this effect. There is some evidence that rituximab may increase your risk of contracting hepatitis B or C. Patients who receive the drug should be vaccinated against tetanus, diphtheria, pertussis (whooping cough), measles, mumps, and rubella. The use of rituximab is associated with adverse effects. Common side effects include nausea, diarrhea, fatigue, fever, chills, headache, vomiting, abdominal pain, cough, sore throat, runny nose, mouth sores, changes in the color of urine, or symptoms of hormone imbalance. In rare cases, patients have experienced heart problems or allergic reactions after receiving rituximab. Rituximab is used to treat certain types of cancer. It works by destroying B cells that play a role in immune response. By removing these cells, patients are less likely to develop resistance to cancer cells.